Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole

Folia Pharmacologica Japonica

Volumn 123, Issue 6, 2004, Pages 429-440

  Kohno, Yasuko ^a   Takeuchi, Shougo ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

Dopamine agonist; Neuroprotective effects; Parkinson's disease; Pramipexole

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; NEUROTROPHIC FACTOR; PLACEBO; PRAMIPEXOLE; PROTEIN BCL 2; TROPANE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; BINDING AFFINITY; CELL DEATH; CONTROLLED STUDY; CORPUS STRIATUM; DAILY LIFE ACTIVITY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENANTIOMER; EUROPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAPAN; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATION KINETICS; PARKINSON DISEASE; RATING SCALE; RECEPTOR UPREGULATION; REVIEW; ROTATION; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; THIAZOLES;

EID: 3042747944     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.123.429     Document Type: Review

References (40)

1. Olanow CW, Watts RL, Loller WC. An algorithm (Decision tree for the management of Parkinson's disease (2001): Treatment guidelines. Neurology. 2001;56 Suppl 5:S1-S88.
2. Guttman M. Doble-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International pramipexole-bromocriptine study group. Neurology. 1997;49:1060-1065.
3. Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology. 1997;49:724-728.
4. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
5. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord. 2003;18:1149-1156.
6. Armer JA. Tolerability and safety profile of pramipexole in the treatment of Parkinson's disease. Rev Contemp Pharmacother. 2001;12:105-124.
7. Mierau J. Pramipexole: A dopamine-receptor agonist for treatment of Parkinson's disease. Clin Neuropharmacol. 1995;18:S195-S206.
8. 4 receptors. Eur J Pharmacol. 1995;290:29-36.
9. 2 receptor agonist. Eur J Pharmacol. 1992;215:161-170.
10. Domino EF, Ni L, Zhang H, Kohno Y, Sasa M. Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl 1,2,3, 6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys. J Pharmacol Exp Ther. 1998;287:983-987.
11. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol. 1997;324:31-37.
12. Lorenc-Koci E, Wolfarth S. Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. Eur J Pharmacol. 1999;385:39-46.
13. Domino EF, Ni L, Zhang H, Kohno Y, Sasa M. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. Eur J Pharmacol. 1997;325:137-144.
14. Prikhojan A, Brannan T, Yahr MD. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats. J Neural Transm. 2000;107:1159-1164.
15. Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I. Levodopa toxicity and apoptosis. Ann Neurol. 1998;44 Suppl 1:S149-S154.
16. Pardo B, Mena MA, Casarejos MJ, Paino CL, Yebenes JG. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 1995;682:133-143.
17. Ling ZD, Pieri SC, Carvey PM. Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons. Clin Neuropharmacol. 1996;19:360-365.
18. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm. 1997;104:209-228.
19. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999;64:1275-1285.
20. VonVoigtlander PF, Fici GJ, Althaus JS. Pharmacological approaches to counter the toxicity of dopa. Amino Acids. 1998;14:189-196.
21. Parkinson study group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
22. Parkinson study group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
23. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol. 1997;74:51-57.
24. Zou L-L, Xu J, Jankovic J, He Y, Appel SH, Le W-D. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000;281:167-170.
25. 3 receptor dependent and independent mechanisms. Eur J Pharmacol. 2003;475:29-35.
26. Sethy VH, Wu H, Oostveen JA, Hall ED. Neuroprotective effects of the dopamine agonist pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 1997;754:181-186.
27. 3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 1996; 742:80-88.
28. Ferger B, Teismann P, Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res. 2000;883:216-223.
29. Cassarino DS, Fall CP, Smith TS, Bennett Jr JP. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem. 1998;71:295-301.
30. Vu TQ, Ling ZD, Ma SY, et al. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm. 2000;107:159-176.
31. Takata K, Kitamura Y, Kakimura J, Kohno Y, Taniguchi T. Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res. 2000;872:236-241.
32. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther. 1999;289:202-210.
33. Kitamura Y, Kosaka T, Kakimura J, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4- phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1998;54:1046-1054.
34. Abramova NA, Cassarino DS, Khan SM. Painter TW, Bennett Jr. JP. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res. 2002;67:494-500.
35. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y, Taniguchi T. Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol. 2001;417:59-67.
36. Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm. 2000;107:1165-1173.
37. Ling ZD, Tong CW, Carvey PM. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures. Brain Res. 1998;791:137-145.